Thank you for exploring Full Spectrum Synergy with OM Extracts! We offer playshops, learning experiences, and literature which are all grounded by the research findings of peer-reviewed scientific references. Email firstname.lastname@example.org to learn about free trainings for Oregon dispensaries and free resources for Cannabis professionals around the world!
What is CBG? Cannabigerol (CBG) is a common cannabinoid that has been getting plenty of scientific attention recently. The Cannabis plant can contain upwards of 100+ Cannabinoids, and CBG is the precursor to all Cannabinoids in immature Cannabis plants. Despite how common it is in low potencies in immature plants, CBG is still quite rare in finished Cannabis flowers at large therapeutic doses. Oregon CBD has bred a variety called “CBG White” which we have available now. Read on for more about CBG, or skip straight to our Canna-Lite page for more about our CBG White!
Check out some of the latest CBG Research:
- Stress and Anxiety: CBG may affect serotonin and adrenaline uptake, affecting stress/anxiety and typically boosting mood. In this article, the authors reference CBG as “highly potent against for α2 adrenoceptor and a blocker of serotonin 5-HT1A receptor [which] underscores the potential importance of [CBG] and other alkaloids in the psychoactive profile of cannabis.” https://pubmed.ncbi.nlm.nih.
- Pain Relief: “Based on its antioxidant activities, CBG may hold great promise as an anti-oxidant agent and therefore used in clinical practice as a new approach in oxidative-stress related disorders.” https://pubmed.ncbi.nlm.nih.
- Neuroprotection, Neuromodulators, and Antioxidant Effects: https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC7279038/ and https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC6073490/. “Neuroprotective and Neuromodulatory Effects Induced by Cannabidiol and Cannabigerol in Rat Hypo-E22 cells and Isolated Hypothalamus” is a fascinating read, with this take-home message: “The CBD modulates hypothalamic neuromodulators consistently with its anorexigenic role, whereas the CBG effect on the same mediators suggests alternative mechanisms, possibly involving peripheral pathways.” In other words, CBD and CBG may both have big positive effects on the part of the brain responsible for regulating temperature, hunger, sleep, and hormones: the thalamus. Neuroprotectors and neuromodulators repair, rebuild and regenerate the nervous system, its cells, structures, and functions.
- Autoimmune Disorders: https://www.ncbi.nlm.nih.gov/
- Multiple Sclerosis / MS: https://pubmed.ncbi.nlm.nih.
- Cancer: https://academic.oup.com/
- Inflammatory Bowel Disease: “The CB2 receptor pathway was also found to modulate the favorable effects of cannabigerol (CBG), a non-psychotropic cannabinoid capable of reducing nitric oxide production in macrophages and attenuating murine DNBS-induced colitis in both a preventive (pretreatment) model and therapeutic (established colitis) model” https://www.ncbi.nlm.nih.gov/
- MRSA, the deadly hospital bacteria: Uncovering the hidden antibiotic potential of Cannabis is an in-depth journal article about CBG and MRSA, and notes that Cannabinoids are much safer than most commercially-available antibacterial agents due to the antibiotic resistance of many common bacteria.
- Dental Health: CBG along with other cannabinoids “were more effective in reducing the bacterial colony count in dental plaques as compared to the well-established synthetic oral care products such as Oral B and Colgate.” The Pub Med article Comparison of Efficacy of Cannabinoids versus Commercial Oral Care Products in Reducing Bacterial Content from Dental Plaque concludes “cannabinoids have the potential to be used as an effective antibacterial agent against dental plaque-associated bacteria. Moreover, it provides a safer alternative for synthetic antibiotics to reduce the development of drug resistance.”
Peer-reviewed article roundup for FULL SPECTRUM SYNERGY PLAYSHOPS:
Andre, Christelle M., et al. “Cannabis Sativa: The Plant of the Thousand and One Molecules.” Frontiers in Plant Science, vol. 7, 2016, doi:10.3389/fpls.2016.00019.
Izzo, Angelo A, et al. “Non-Psychotropic Plant Cannabinoids: New Therapeutic Opportunities from an Ancient Herb.” Trends in Pharmacological Sciences, vol. 30, no. 12, 2009, p. 609., doi:10.1016/j.tips.2009.10.007.
Maccallum, Caroline A., and Ethan B. Russo. “Practical Considerations in Medical Cannabis Administration and Dosing.” European Journal of Internal Medicine, vol. 49, 2018, pp. 12–19., doi:10.1016/j.ejim.2018.01.004.
McPartland, J. M., & Russo, E. B. (2001). Cannabis and cannabis extracts: Greater than the sum of their parts? Journal of Cannabis Therapeutics, 1(3–4), 103–132. http://doi.org/10. 1300/J175v01n03_08.
Romano, Luigi., Hazekamp, Arno. “Cannabis oil: chemical evaluation of an upcoming cannabis based medicine.” IACM Journal, vol. 1(1), 2013, pp. 1-11.
Russo, Ethan & Marcu, Jahan. (2017). Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Advances in Pharmacology. . 10.1016/bs.apha.2017.03.004.
Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364. http:// doi.org/10.1111/j.1476-5381.2011.01238.x.
Russo, E. B. (2013). Cannabis strains: Do cannabis strains differ? Retrieved January 18, 2017, from http://www.cannabis-med.org/index.php?tpl¼faq&red¼faqlist&id¼278&lng¼en.
Russo, E. B. (2019). The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain,” No Gain. Frontiers in Plant Science”. Vol 9, Article 1969. Doi: 10.3389/fpls.2018.01969 https://www.frontiersin.org/articles/10.3389/fpls.2018.01969/full
“…the case for Cannabis synergy via the “entourage effect” is currently sufficiently strong as to suggest that one molecule is unlikely to match the therapeutic and even industrial potential of Cannabis itself as a phytochemical factory.”
Russo, E. B., & Guy, G. W. (2006). A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Medical Hypotheses, 66(2), 234–246. http://dx.doi.org/10.1016/j.mehy.2005.08.026.
Sinclair, Justin. An introduction to cannabis and the endocannabinoid system. Australian Journal of Herbal Medicine, Vol. 28, No. 4, 2016: 107-125.
Whittle, Brian A., et al. “Prospects for New Cannabis-Based Prescription Medicines.” Journal of Cannabis Therapeutics, vol. 1, no. 3-4, 2001, pp. 183–205., doi:10.1300/j175v01n03_12.
Zgair, A., Wong, J. C., Lee, J. B., Mistry, J., Sivak, O., Wasan, K. M., Hennig, I. M., Barrett, D. A., Constantinescu, C. S., Fischer, P. M., … Gershkovich, P. (2016). Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. American journal of translational research, 8(8), 3448-59. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009397/
Zgair, A., et al. (2017). Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. Scientific Reports, 7, Article 14542. https://www.nature.com/articles/s41598-017-15026-z/